For instance, in the trial of the anti-C1q mAb ANX-005 in HD, retrospective analysis showed that a subset of patients with high C4/C4a ratios (indicative of classical pathway activation) responded best to the drug (75% vs. 36% response) [244]. The gene discussed is C4A; the disease is Huntington disease.